Tolbutamide Controls Glucagon Release from Mouse Islets Differently Than Glucose: Involvement of K(ATP) Channels from Both α-cells and δ-cells

Overview

Journal Diabetes

Specialty Endocrinology

Date 2013 Feb 6

PMID 23382449

Citations 44

Authors

Rui Cheng-Xue

Ana Gomez-Ruiz

Nancy Antoine

Laura A Noel

Hee-Young Chae

Magalie A Ravier

Fabrice Chimienti

Frans C Schuit

Patrick Gilon

Affiliations

Soon will be listed here.

Abstract

We evaluated the role of ATP-sensitive K⁺ (K(ATP)) channels, somatostatin, and Zn²⁺ in the control of glucagon secretion from mouse islets. Switching from 1 to 7 mmol/L glucose inhibited glucagon release. Diazoxide did not reverse the glucagonostatic effect of glucose. Tolbutamide decreased glucagon secretion at 1 mmol/L glucose (G1) but stimulated it at 7 mmol/L glucose (G7). The reduced glucagon secretion produced by high concentrations of tolbutamide or diazoxide, or disruption of K(ATP) channels (Sur1(-/-) mice) at G1 could be inhibited further by G7. Removal of the somatostatin paracrine influence (Sst(-/-) mice or pretreatement with pertussis toxin) strongly increased glucagon release, did not prevent the glucagonostatic effect of G7, and unmasked a marked glucagonotropic effect of tolbutamide. Glucose inhibited glucagon release in the absence of functional K(ATP) channels and somatostatin signaling. Knockout of the Zn²⁺ transporter ZnT8 (ZnT8(-/-) mice) did not prevent the glucagonostatic effect of glucose. In conclusion, glucose can inhibit glucagon release independently of Zn²⁺, K(ATP) channels, and somatostatin. Closure of K(ATP) channels controls glucagon secretion by two mechanisms, a direct stimulation of α-cells and an indirect inhibition via somatostatin released from δ-cells. The net effect on glucagon release results from a balance between both effects.

Citing Articles

Real-time detection of somatostatin release from single islets reveals hypersecretion in type 2 diabetes.

Yang M, Mandal K, Sodergren M, Dumral O, Winroth L, Tengholm A Acta Physiol (Oxf). 2025; 241(2):e14268.

PMID: 39803760 PMC: 11726413. DOI: 10.1111/apha.14268.

The role of mu-opioid receptors in pancreatic islet α-cells.

Kong C, Castro D, Lee J, Piston D J Mol Endocrinol. 2024; 74(1).

PMID: 39475846 PMC: 11875080. DOI: 10.1530/JME-24-0060.

Leucine Suppresses α-Cell cAMP and Glucagon Secretion via a Combination of Cell-Intrinsic and Islet Paracrine Signaling.

Knuth E, Foster H, Jin E, Ekstrand M, Knudsen J, Merrins M Diabetes. 2024; 73(9):1426-1439.

PMID: 38870025 PMC: 11333377. DOI: 10.2337/db23-1013.

The role of mu-opioid receptors in pancreatic islet alpha cells.

Kong C, Castro D, Lee J, Piston D bioRxiv. 2024; .

PMID: 38798528 PMC: 11118541. DOI: 10.1101/2024.05.13.593899.

α-cell electrophysiology and the regulation of glucagon secretion.

Gao R, Acreman S, Ma J, Abdulkader F, Wendt A, Zhang Q J Endocrinol. 2023; 258(2).

PMID: 37159865 PMC: 10326640. DOI: 10.1530/JOE-22-0295.

References

Munoz A, Hu M, Hussain K, Bryan J, Aguilar-Bryan L, Rajan A . Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement. Endocrinology. 2005; 146(12):5514-21. DOI: 10.1210/en.2005-0637. View

Hoy M, Olsen H, Bokvist K, Buschard K, Barg S, Rorsman P . Tolbutamide stimulates exocytosis of glucagon by inhibition of a mitochondrial-like ATP-sensitive K+ (KATP) conductance in rat pancreatic A-cells. J Physiol. 2000; 527 Pt 1:109-20. PMC: 2270047. DOI: 10.1111/j.1469-7793.2000.00109.x. View

Quoix N, Cheng-Xue R, Mattart L, Zeinoun Z, Guiot Y, Beauvois M . Glucose and pharmacological modulators of ATP-sensitive K+ channels control [Ca2+]c by different mechanisms in isolated mouse alpha-cells. Diabetes. 2008; 58(2):412-21. PMC: 2628615. DOI: 10.2337/db07-1298. View

de Heer J, Rasmussen C, Coy D, Holst J . Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008; 51(12):2263-70. DOI: 10.1007/s00125-008-1149-y. View

Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim C . Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes. 2005; 54(6):1808-15. DOI: 10.2337/diabetes.54.6.1808. View

Detimary P, Dejonghe S, Ling Z, Pipeleers D, Schuit F, Henquin J . The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. J Biol Chem. 1998; 273(51):33905-8. DOI: 10.1074/jbc.273.51.33905. View

Hjortoe G, Hagel G, Terry B, Thastrup O, Arkhammar P . Functional identification and monitoring of individual alpha and beta cells in cultured mouse islets of Langerhans. Acta Diabetol. 2005; 41(4):185-93. DOI: 10.1007/s00592-004-0164-9. View

Unger R, Cherrington A . Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012; 122(1):4-12. PMC: 3248306. DOI: 10.1172/JCI60016. View

Miki T, Liss B, Minami K, Shiuchi T, Saraya A, Kashima Y . ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci. 2001; 4(5):507-12. DOI: 10.1038/87455. View

10.

Schuit F, de Vos A, Farfari S, Moens K, Pipeleers D, Brun T . Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in beta cells. J Biol Chem. 1997; 272(30):18572-9. DOI: 10.1074/jbc.272.30.18572. View

11.

Low M, Parlow A, Ramirez J, Kumar U, Patel Y, Rubinstein M . Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth. J Clin Invest. 2001; 107(12):1571-80. PMC: 200191. DOI: 10.1172/JCI11941. View

12.

Olsen H, Theander S, Bokvist K, Buschard K, Wollheim C, Gromada J . Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology. 2005; 146(11):4861-70. DOI: 10.1210/en.2005-0800. View

13.

Shiota C, Rocheleau J, Shiota M, Piston D, Magnuson M . Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor. Am J Physiol Endocrinol Metab. 2005; 289(4):E570-7. DOI: 10.1152/ajpendo.00102.2005. View

14.

Gregorio F, Ambrosi F, Cristallini S, Pedetti M, Filipponi P, Santeusanio F . Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes Res Clin Pract. 1992; 18(3):197-206. DOI: 10.1016/0168-8227(92)90146-i. View

15.

Lemaire K, Ravier M, Schraenen A, Creemers J, Van de Plas R, Granvik M . Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. Proc Natl Acad Sci U S A. 2009; 106(35):14872-7. PMC: 2736467. DOI: 10.1073/pnas.0906587106. View

16.

Gromada J, Ma X, Hoy M, Bokvist K, Salehi A, Berggren P . ATP-sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1-/- mouse alpha-cells. Diabetes. 2004; 53 Suppl 3:S181-9. DOI: 10.2337/diabetes.53.suppl_3.s181. View

17.

Walker J, Ramracheya R, Zhang Q, Johnson P, Braun M, Rorsman P . Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?. Diabetes Obes Metab. 2011; 13 Suppl 1:95-105. DOI: 10.1111/j.1463-1326.2011.01450.x. View

18.

Vieira E, Salehi A, Gylfe E . Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia. 2006; 50(2):370-9. DOI: 10.1007/s00125-006-0511-1. View

19.

Pipeleers D, Schuit F, Van Schravendijk C, Van De Winkel M . Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology. 1985; 117(3):817-23. DOI: 10.1210/endo-117-3-817. View

20.

Zhang C, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H . The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009; 325(5940):607-10. DOI: 10.1126/science.1172256. View